CREATE Medicines Nabs $122M Series B

CREATE Medicines raised $122 million in a Series B round co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners.

Alexandria Venture Investments and other backers also joined the financing.

The funding will help advance its in vivo immune programming platform and pipeline of CAR therapies.

The goal is scalable, repeat-dose cell therapies that can be delivered inside the body for cancer and autoimmune disease.